BlaidsX Micro vs Otofonix Groove

The BlaidsX Micro is a budget-priced OTC hearing aid that earned a B grade with a SoundScore of 3.0/5 in HearAdvisor's lab testing. At $499, it sits in the entry-level price tier but ranks #59 of 65 OTC hearing aids tested, placing it in the bottom portion of its category. In our testing, the BlaidsX Micro delivered mixed results across key performance areas. Its standout strength is excellent feedback handling, scoring a perfect 5.0/5 after tuning—0.46 points above the category average. This means users are unlikely to experience whistling or squealing during normal use. Speech in quiet environments scored 2.9/5, which is above the category average by 0.09 points, though this remains a mixed absolute score. The device shows notable weaknesses in several areas. Speech in noise performance is low at 1.0/5, falling 0.48 points below the OTC category average. Own-voice comfort also scored low at 1.0/5, sitting 1.51 points below average—users may notice their own voice sounds boomy or unnatural. Music streaming is not a viable use case with this device, scoring 0.0/5, which is 1.92 points below the category average. Budget-conscious shoppers should note that several competitors in the same price range offer significantly better overall performance, including the Elehear Beyond (4.34/5) and Apple AirPods Pro 2 (4.04/5). The BlaidsX Micro may suit buyers primarily concerned with feedback-free amplification in quiet settings, but those needing help in noisy environments or who want streaming capabilities should consider alternatives.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.